Dynavax Technologies Corporation (LON:0IDA)
London · Delayed Price · Currency is GBP · Price in USD | Market Cap | n/a |
| Revenue (ttm) | 245.88M +26.7% |
| Net Income | -32.29M |
| EPS | -0.27 |
| Shares Out | n/a |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 183 |
| Average Volume | 391 |
| Open | 15.50 |
| Previous Close | 15.50 |
| Day's Range | 15.49 - 15.50 |
| 52-Week Range | 9.28 - 15.73 |
| Beta | 0.93 |
| RSI | 77.67 |
| Earnings Date | Feb 19, 2026 |
About Dynavax Technologies
Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States and internationally. The company offers HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in adults aged 18 years and older; and CpG 1018, the adjuvant used in HEPLISAV-B. It also develops rF1V, a plague vaccine candidate in Phase 2 clinical trial; and Z-1018, an investigational vaccine candidate in Phase 1/2 clinical trial for the pr... [Read more]
News
Sanofi (SNY) Finalizes Acquisition of Dynavax to Enhance Vaccine Portfolio
Sanofi (SNY) Finalizes Acquisition of Dynavax to Enhance Vaccine Portfolio
Ciena Set to Join S&P 500; Arrowhead Pharmaceuticals to Join S&P MidCap 400; ADT and OneSpaWorld Holdings to Join S&P SmallCap 600
NEW YORK, Feb. 4, 2026 /PRNewswire/ -- S&P Dow Jones Indices will make the following changes to the S&P 500, S&P MidCap 400, S&P SmallCap 600: S&P MidCap 400 constituent Ciena Corp. (NYSE: CIEN) will...
Dynavax President and COO Sells 114,000 Shares on Sanofi Acquisition News
This vaccine-focused biotech reported a significant insider sale as it advances its hepatitis B franchise and global partnerships.
HARBOR CAPITAL ADVISORS, INC. Sells 5 Shares of Dynavax Technologies Corp (DVAX)
HARBOR CAPITAL ADVISORS, INC. Sells 5 Shares of Dynavax Technologies Corp (DVAX)
Dynavax (DVAX) Sees Stock Rise Amid New Bidder Interest
Dynavax (DVAX) Sees Stock Rise Amid New Bidder Interest
Dynavax gains on disclosure another bidder interested after deal announced
Dynavax (DVAX) stock rises after a mystery bidder shows interest despite Sanofi’s $2.2B, $15.50/share deal.
$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Dynavax Technologies Corporation (NASDAQ: DVAX)
NEW YORK, Jan. 5, 2026 /PRNewswire/ -- Class Action Attorney Juan Monteverde with Monteverde & Associates PC (the "M&A Class Action Firm"), has recovered millions of dollars for shareholders and is ...
Dynavax Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Dynavax Technologies Corporation - DVAX
NEW YORK and NEW ORLEANS, Dec. 30, 2025 /PRNewswire/ -- Former Attorney General of Louisiana Charles C. Foti, Jr., Esq.
CORRECTING and REPLACING Dynavax Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Dynavax Technologies Corporation - DVAX
NEW YORK CITY & NEW ORLEANS--(BUSINESS WIRE)--Please replace the release issued December 29, 2025 with the following corrected version due to multiple revisions. The updated release reads: DYNAVAX INV...
Shareholder Alert: The Ademi Firm investigates whether DigitalBridge Group, Inc. is obtaining a Fair Price for its Public Shareholders
MILWAUKEE, Dec. 29, 2025 /PRNewswire/ -- The Ademi Firm is investigating DigitalBridge (Nasdaq: DVAX) for possible breaches of fiduciary duty and other violations of law in its recently announced tran...
Stock Market Today: Dow Jones, S&P 500 Futures Slip After Christmas Day—Nvidia, Sobr Safe, Biohaven In Focus
U.S. stock futures slipped on Friday after Wednesday’s higher close. Futures of major benchmark indices fell. The New York Stock Exchange closed early at 1 p.m. ET on Wednesday and remained closed Thu...
Company News for Dec 26, 2025
Companies In The News Are: NVDA, NKE, AAPL, DVAX, SNY, INTC.
Sanofi-Dynavax: A Conservative Vaccine Deal With Upside Tail Risk
Sanofi acquires Dynavax for $2.2B, boosting its vaccine portfolio with HEPLISAV-B and a shingles candidate. Click for my latest analysis of SNY and DVAX stocks.
Dynavax Technologies (DVAX) Shares Are Trending Overnight — Here's Why
Dynavax Technologies Corporation (NASDAQ: DVAX) shares are trending on Thursday. Check out the current price of DVAX stock here . Shares of the California-based biopharmaceutical company surged 38.19...
Nike, Omeros Corporation, Micron Technology, Intel And Dynavax Technologies: Why These 5 Stocks Are On Investors' Radars Today
Wall Street experienced a modest rally as the S&P 500 reached new heights, closing up 0.2% in a shortened session before the Christmas break. The index’s year-to-date gains now stand at 17%. The Dow J...
Why Dynavax Stock Soared Today
A healthcare titan wants to buy the biotech's vaccines.
What Sanofi Is Getting Through The Acquisition Of Dynavax
Dynavax Technologies (DVAX) Receives Downgrade to Market Perform by William Blair | DVAX Stock News
Dynavax Technologies (DVAX) Receives Downgrade to Market Perform by William Blair | DVAX Stock News
Wednesday Sector Leaders: Drugs, Biotechnology Stocks
In trading on Wednesday, drugs shares were relative leaders, up on the day by about 1.6%. Leading the group were shares of Omeros, up about 84.5% and shares of Dynavax Technologies up about 38.6% on t...
Sanofi to Acquire Dynavax, Expanding Vaccine Portfolio
Sanofi to Acquire Dynavax, Expanding Vaccine Portfolio
Shareholder Alert: The Ademi Firm investigates whether Dynavax Technologies Corporation is obtaining a Fair Price for its Public Shareholders
MILWAUKEE , Dec. 24, 2025 /PRNewswire/ -- The Ademi Firm is investigating Dynavax (Nasdaq: DVAX) for possible breaches of fiduciary duty and other violations of law in its recently announced transacti...
Shares of Dynamax Are Up Nearly 40% Today. Here's Why The Stock Is Flying
Shares of Dynavax Technologies (DVAX) skyrocketed after French drugmaker Sanofi (SNY) said it would buy the biopharmaceutical firm for $2.2 billion to expand its Hepatitis B offerings and enter the sh...
Sanofi to Buy Dynavax for $2.2B to Boost Adult Vaccine Franchise
SNY's $2.2 billion deal for Dynavax adds Heplisav-B, a shingles candidate, and other vaccine programs, strengthening its adult vaccine franchise and pipeline.
US markets today: Wall Street holds near record highs in holiday-thinned trade; stocks mark time as Christmas closure nears
US stocks traded near record highs in a quiet session ahead of Christmas. Dynavax Technologies saw a significant surge on acquisition news. Global markets showed mixed movements, while gold and silver...